Stryker Corp

The Law Offices of Frank R. Cruz is investigating Stryker Corporation (SYK) for potential securities law violations due to supply disruptions leading to significant backorders and lost sales, which caused the stock to drop in July and September 2026. The company initially expected a quick resolution but later confirmed the issues would persist, impacting investor confidence. Investors who suffered losses are encouraged to contact the law firm for recovery options.

The Law Offices of Frank R. Cruz is continuing its investigation into Stryker Corporation (NYSE: SYK) for potential violations of federal securities laws. This stems from investor losses following the company's Q2 2026 report, which cited supply disruptions and backorders, causing a 6.43% stock drop. Further investor injury occurred when the CFO indicated these manufacturing issues would persist into Q3, leading to an additional 8.8% decline in share price.

Intuitive Surgical (ISRG) has seen its stock gain nearly 12% in the past month, driven by investor confidence in robotic-assisted surgery and an expanding product portfolio. The company is set to report strong third-quarter results, with sustained operational momentum and growth in da Vinci and Ion procedures. Despite facing challenges like moderating U.S. procedure growth and competition, analysts suggest ISRG, with a Zacks Rank #2 (Buy), remains an attractive investment for long-term growth in the robotic surgery market.

Stryker has received FDA 510(k) clearance for its Sonopet® 3 ultrasonic bone and soft tissue removal platform. Developed with surgeon input, Sonopet 3 offers enhanced power, precision, and versatility, incorporating new technologies like RISE and Pulse Control for improved surgical workflows. Clinical cases are expected to begin in October, with a full commercial launch later this fall.

Stryker Corporation (SYK) is set to report its Q3 fiscal 2026 earnings on October 29, with analysts anticipating diluted earnings of $3.59 per share, a 12.5% year-over-year increase. Despite a recent stock drop due to a cyberattack, manufacturing constraints, and CEO transition concerns, Wall Street analysts maintain a "Strong Buy" consensus rating with significant upside potential. The company is also addressing supply chain issues and has made a strategic investment in CMR Surgical.

Stryker (SYK) stock has fallen 22.8% over the past year, leading Simply Wall St to suggest it is currently undervalued based on a Discounted Cash Flow (DCF) model. The company's recent $400 million investment in CMR Surgical and exclusive U.S. rights to the Versius system are expected to support future cash generation, despite near-term share price pressure due to a planned CEO transition in 2027. The analysis indicates that Stryker's intrinsic value, supported by strong projected free cash flows, is meaningfully above its current share price of US$282.55.

Stryker has announced the FDA 510(k) clearance of its new Sonopet® 3 ultrasonic bone and soft tissue removal platform. Developed with surgeon input, this device offers enhanced power, precision, and versatility, incorporating advanced technologies like RISE and Pulse Control for improved surgical workflows. Clinical cases are expected to begin in October, with a full commercial launch later this fall.

Stryker has announced the FDA 510(k) clearance for Sonopet® 3, its latest ultrasonic bone and soft tissue removal platform. Developed with extensive surgeon feedback, this new system offers enhanced power, precision, and versatility. Key features include RISE (Reimagined Integrated Surgical Experience) and Pulse Control, designed to streamline surgical workflows and improve tissue resection capabilities.

Stryker (SYK) has received FDA 510(k) clearance for its latest ultrasonic bone and soft tissue removal platform, Sonopet 3, developed with significant input from hundreds of surgeons. The new platform features RISE for connected surgical workflows and Pulse Control for regulating tissue resection, aiming for enhanced power, precision, and versatility. First clinical cases are expected in October, with a full commercial launch anticipated later this fall.

Stryker has received FDA 510(k) clearance for its Sonopet® 3, an ultrasonic bone and soft tissue removal platform developed with surgeon collaboration. This new platform offers enhanced power, precision, and versatility, incorporating advanced technologies like RISE and Pulse Control for improved surgical workflows. Clinical cases are expected to begin in October, with a full commercial launch later this fall.